Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR
Marketer
Danavish Healthcare
Salt Composition
Metformin (500mg) + Voglibose (0.2mg)
Overview Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR
Danavish Metformin/Voglibose 500mg/0.2mg extended-release tablets are classified as antidiabetic medications. This combination therapy is indicated for adult patients with type 2 diabetes to manage blood glucose levels. Administer this medication with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial, even with well-controlled blood sugar, as abrupt cessation can lead to elevated glucose levels, increasing the risk of complications like nephropathy, retinopathy, neuropathy, and peripheral vascular disease. This medication is part of a comprehensive diabetes management plan that includes a healthy diet, exercise, and weight management as directed by your doctor. Lifestyle modifications are essential for effective diabetes control. Potential side effects include nausea, altered taste perception, appetite changes, flatulence, abdominal discomfort, diarrhea, and skin rashes. These are usually transient and self-limiting; however, consult your physician if symptoms persist or are concerning. Your doctor can offer strategies to manage or treat these side effects. This medicine is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of heart disease should inform their physician before starting treatment, as it may be unsuitable. Pregnant or lactating women should consult their doctor prior to use. Regular blood glucose monitoring is necessary, and your physician may order blood tests to assess blood cell counts and liver function.
Uses of Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR
Managing type 2 diabetes
Major Benefits of Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR:
Follow your doctor's instructions precisely regarding dosage and treatment length for Danavish Metformin+Voglibose 500mg/0.2mg SR Tablets. Ingest the tablets whole; avoid crushing, chewing, or breaking them. Administer this medication with food.
Common Side effects of Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR:
- Flatulence
- Diarrhea
- Abdominal pain
- Vomiting
- Decreased appetite
How to use Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Danavish Metformin+Voglibose 500mg/0.2mg Sustained-Release Tablets should be administered with meals.
How Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR works:
Danavish combines metformin (500mg) and voglibose (0.2mg) in a sustained-release tablet to manage blood sugar levels.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking Danavish Metformin+Voglibose 500mg/0.2mg SR tablets is not advisable.
PregnancyCONSULT YOUR DOCTOR
The use of Danavish Metformin+Voglibose 500mg/0.2mg SR tablets during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing this medication. Physician consultation is recommended.
Breast feedingCONSULT YOUR DOCTOR
Use of Danavish Metformin+Voglibose 500mg/0.2mg SR tablets during breastfeeding is likely unsafe. Preliminary human evidence indicates potential transfer to breast milk, posing a risk to the infant.
DrivingSAFE
Driving ability is typically unaffected by Danavish Metformin+Voglibose 500mg/0.2mg SR Tablets. Nevertheless, patients should be aware of the potential for low blood sugar (hypoglycemia) if this medication is taken alongside other diabetes treatments like sulfonylureas, insulin, or repaglinide.
KidneyCAUTION
Patients with kidney impairment should exercise caution when using Danavish Metformin+Voglibose 500mg/0.2mg SR tablets, as dose modification may be necessary. Individuals with severe kidney disease should avoid this medication. Regular kidney function monitoring is recommended during treatment. Physician consultation is advised.
LiverCONSULT YOUR DOCTOR
Insufficient data exists regarding the use of Danavish Metformin+Voglibose 500mg/0.2mg SR tablets in individuals with hepatic impairment. Physician consultation is advised.
What if you forget to take Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR :
Should you forget a Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR, ingest it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing pattern. Never take a double dose.
Facts to Know About Danavish Metformin+Voglibose 500mg/0.2mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes medication |



